Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Esperion Therapeutics is a specialty pharmaceutical company commercializing oral, non-statin LDL-cholesterol lowering therapies (bempedoic acid) for cardiovascular disease patients. The company markets NEXLETOL and NEXLIZET in the US and has licensed rights to Daiichi Sankyo for ex-US markets. Recent 186% revenue growth reflects commercial ramp following positive CLEAR Outcomes cardiovascular outcomes trial data published in March 2023, which demonstrated 13% reduction in major adverse cardiovascular events.
Esperion generates revenue through direct sales to specialty pharmacies and wholesalers in the US cardiovascular market. The company targets statin-intolerant patients and those requiring additional LDL-lowering beyond statins, addressing an estimated 30-40 million patient population in the US. Pricing power derives from differentiated mechanism of action (ATP citrate lyase inhibitor) and outcomes data showing cardiovascular event reduction. Gross margins of 79% reflect low cost of goods for small molecule oral therapy. The company maintains a specialized 120-person sales force focused on high-prescribing cardiologists and endocrinologists. Ex-US, Daiichi Sankyo handles commercialization with Esperion receiving tiered royalties on net sales.
Quarterly prescription volume trends (TRx and NBRx data from IQVIA) - market expects continued 30-40% sequential growth
Payer coverage expansion and prior authorization removal - currently ~80% commercial lives covered, Medicare Part D formulary positioning critical
Daiichi Sankyo ex-US launch progress in Europe (EMA approved 2020) and Japan - royalty revenue acceleration
Gross-to-net pricing adjustments and rebate trends - currently running ~50% gross-to-net, in line with specialty pharma
Cash burn rate and path to sustained profitability - company near breakeven operationally but negative FCF of $30M TTM
Competitive threat from PCSK9 inhibitors (Repatha, Praluent) gaining oral formulations or pricing becoming more aggressive - injectable biologics currently $5,000-6,000 annually versus NEXLETOL ~$4,000
Inclisiran (Leqvio) twice-yearly injectable gaining market share in statin-intolerant segment - Novartis pricing at $3,250 annually with superior dosing convenience
Medicare Part D negotiation risk under Inflation Reduction Act - products could face price controls if selected for negotiation in 2027-2029 cycles
Generic bempedoic acid entry post-patent expiration (key composition of matter patents expire 2030-2032) - limited exclusivity runway
Statin manufacturers (Pfizer Lipitor generic, AstraZeneca Crestor) maintaining dominance through inertia and $10-20/month generic pricing despite tolerability issues in 10-15% of patients
Amgen and Sanofi/Regeneron expanding PCSK9 inhibitor access through aggressive rebating and outcomes data - cardiovascular outcomes superiority versus bempedoic acid unclear in head-to-head
Novartis Leqvio gaining preferred formulary status due to twice-yearly dosing versus daily oral - adherence advantage in real-world setting
Negative tangible book value and accumulated deficit of approximately $1.8B - company has burned significant cash reaching commercialization
Current ratio of 1.0x indicates tight liquidity - cash position of ~$150M provides 12-18 month runway at current burn rate without additional financing
Potential need for equity raise or debt financing if revenue growth disappoints - dilution risk to existing shareholders given $700M market cap
Negative ROA of -29% reflects asset-light model but also ongoing losses - path to positive ROE depends on sustained revenue growth
low - Prescription pharmaceutical demand for chronic cardiovascular disease treatment is largely non-discretionary and insulated from economic cycles. Patient population skews older (Medicare-eligible) with insurance coverage. However, commercial insurance mix and patient out-of-pocket costs can be affected by employment levels and benefit design changes during recessions.
Rising rates create modest headwind through higher discount rates applied to future cash flows in DCF valuations, compressing biotech/pharma multiples. Company carries minimal debt ($20M convertible notes), so direct financing cost impact is negligible. However, as pre-profitable growth company, higher risk-free rates make equity financing more dilutive and reduce relative attractiveness versus established pharma with dividends.
Minimal direct credit exposure. Revenue is primarily from large pharmaceutical wholesalers (McKesson, AmerisourceBergen, Cardinal Health) with strong credit profiles. Patient access depends on insurance coverage, but cardiovascular medications receive priority formulary status. Royalty payments from Daiichi Sankyo (investment grade) carry low counterparty risk.
growth - Company attracts biotech/specialty pharma growth investors focused on commercial execution and revenue inflection. Recent 186% revenue growth and 90% one-year return appeal to momentum investors. Negative FCF and lack of profitability exclude value and income investors. High volatility and binary outcomes (payer coverage decisions, competitive threats) suit risk-tolerant growth mandates. Institutional ownership likely concentrated in healthcare-focused funds.
high - Small-cap biotech with $700M market cap exhibits significant volatility driven by quarterly prescription data, payer coverage announcements, and competitive developments. Stock has demonstrated 74% six-month return, indicating momentum-driven trading. Limited analyst coverage and low float amplify price swings. Beta likely 1.5-2.0x relative to broader market.
